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Results: The median survival time was 1.82 years (95% CI – 1.57; 
2.06). A univariable analysis was performed for SUV descriptors and 
metabolic features. Results for the statistically significant metabolic 
features (p-value<0.05) are shown in Table 1. 
AVAI of 0.5 and 1, and AVRI of 10% showed a high correlation (Pearson 
correlation = 0.999,0.992 and 0.995) with GTV. 
Both RVRI of 80% and 90% (Pearson correlation =0.888) revealed a 
good prognostic value, outperforming the SUV descriptors. 
  
Conclusions: We investigated new approaches based on metabolic 
metrics derived from baseline PET images to analyze survival in NSCLC 
patients. AVAIof 0.5 and 1, and AVRI of 10% are a surrogate of tumor 
volume: highly correlated (≈1) with GTV and exhibiting identical 
performance. Metabolic features regarding portion of tumor above 
higher uptakes outperformed the most commonly used SUV metrics, 
maximum and mean. Currently, further investigation is ongoing by 
adding new patients to the analysis and applying results to an external 
dataset. 
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Purpose/Objective: SBRT for early stage non-small cell lung cancer is 
increasingly applied by many centres. Therefore, FDG-PET/CT is 
widely accepted as mandatory pre-treatment staging procedure, 
however, its timing is not standardised. In patients with locally 
advanced NSCLC, a high rate of tumou rgrowth and disease 
progression has been demonstrated when repeating the FDG-PET/CT 
during the SBRT planning phase accounting to about 30% upstaging 
probability within three weeks. The aim of this study was to 
investigate the FDG-PET/CT progression rate prior to SBRT. 
Materials and Methods: Nineteen consecutive early stage NSCLC 
patients referred for SBRT to the University Hospital Freiburg between 
08/2008 and 08/2011 were retrospectively analysed. All patients had 
already undergone an FDG-PET/CT scan at the time of referral and 
underwent a second FDG PET/CT for radiation planning purposes. All 
scans were analysed by two investigators blinded for treatment 
outcome regarding: availability of scan, tumour size and thus clinical 
T-stage, maximum standardized uptake value (SUVmax) in the tumour, 
additional FDG uptake in hilar/mediastinal lymph nodes (cN1/2) or at 
distant sites (cM1a/b). Progressive disease (>25% increase of tumour 
diameter on CT or >25% increase in SUVmax) and the time-interval 
between both imaging modalities were related to overall survival. 
Results: Median time interval between the diagnostic and planning 
FDG-PET/CT scan was 43 days (range: 22-140 days). After the planning 
FDG-PET/CT, 3/19 (15.8%) patients were not amenable for SBRT 
anymore due to diagnosis of nodal metastases (interscan interval: 22, 
51, and 95 days, respectively). No patients were found to have distant 
metastases. In the remaining 16 patients, no additional lesions were 
found, but one patient had progression in tumour diameter and two in 
SUVmax values. Notwithstanding, the lesions were still eligible for 
SBRT. Overall, upstaging occurred in 6/19 (31.6%) of patients, all but 
one with an interscan interval of more than 43 days (average 60 days, 
range 22-95 days). Overall, the upstaging probability with an interscan 
interval of less than 3 weeks was 0%. Furthermore, an SUVmax above 
median (9.50) on the diagnostic FDG-PET/CT scan was of borderline 
significance(p=0.06) for overall survival. 
Conclusions: In patients scheduled for SBRT, the rate of tumour 
growth and disease progression seen by repeated FDG-PET/CT was 
lower as compared to the situation in locally advanced disease. 
However, due to the risk of undertreatment of nodal progression in 
15.8% of cases, a timely scheduling of pre-treatment staging FDG-
PET/CT is recommended.  
 
 SYMPOSIUM: IMAGE-BASED ASSESSMENT OF THE 
RESPONSE OF NORMAL TISSUES TO RT  
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Radiation therapy (RT) is a major treatment modality for brain 
tumors.  As combining radiation therapy with chemotherapy and 
molecular targeted therapy is improving survival, neurotoxicity, 
including cognitive function decline and normal tissue necrosis, 
becomes an issue of quality of life.   Clinical symptoms and cognitive 
decline usually occur delayed or late as weeks, months or even years 
after the completion of RT. The clinical outcome ranges from mild, 
reversible damage to irreversible injury.  In the past, efforts to 
develop models to estimate the likelihood of developing radiation-
induced neurotoxicity have been primarily based on the planned 
radiation dose distribution, dose fraction size, and dose volume. 
These analyses have demonstrated their usefulness for permitting the 
safe delivery of higher doses of radiation than have previously been 
possible.  However, there is a broad range of individual patient 
sensitivity that is not reflected by predictions made solely based on 
the physical dose distribution or general clinical features.   If 
individual patient response to radiation could be better estimated 
before or during a course of treatment, it would permit higher doses 
of radiation to be delivered safely to the tumors of patients who is 
relatively radiation resistant, thus prolonging survival without 
increasing complications.   It would be valuable to identify 
biomarkers, including those derived from in vivo imaging, for early 
assessment of individual sensitivity to radiation and prediction of 
delayed and late neurotoxicity. Such biomarkers might provide an 
opportunity to individualize the dose of RT.  Our group has been 
conducting active research in this area.  We have used diffusion tensor 
(DTI) and dynamic contrast enhanced (DCE) MRI to assess individual 
and brain structural sensitivity to radiation.  Structural-variation in 
sensitivity to radiation may be related to the selective cognitive 
decline after brain irradiation.   Our results indicate that combining 
the early changes in the DTI and DCE indices of brain functional 
structures with doses has the potential to improve the prediction of 
delayed or late cognitive decline and/or brain tissue necrosis. 
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Radiation-induced lung toxicity (RILT) is one of the main dose-limiting 
factors in lung cancer treatment. It usually occurs within 3-6 months 
after the start of (chemo)radiotherapy and manifests itself with 
dyspnea, cough and fever. While the delivered dose to the lung is the 
primary cause of lung damage, different patients exhibit different 
susceptibility. In fact, only about 15%-25% of all lung cancer patients 
develop serious dyspnea problems (grade >=2 according to the 
Common Toxicity Criteria (CTC)), despite receiving a similar mean 
lung dose (15-20 Gy) as the rest of patients. It is therefore likely that 
other determinants, including clinical, dosimetric and tumor-related 
features, contribute to the observed individual susceptibility to lung 
damage. Since the heart and the lung form the interrelated 
